1 / 4

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial. Randomized, double-blind, multicenter, controlled trial. 4447 patients with type 2 diabetes and at least one additional cardiovascular risk factor, but with no evidence of renal dysfunction

tymon
Download Presentation

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial • Randomized, double-blind, multicenter, controlled trial. • 4447 patients with type 2 diabetes and at least one additional cardiovascular risk factor, but with no evidence of renal dysfunction • Olmesartan (at a dose of 40 mg once daily) versus placebo for median 3.2 years • Other antihypertensive drugs (except ACE inhibitors and ARBs) were used as required for BP control (<130/80 mm Hg). • The primary outcome was the time to the first onset of microalbuminuria 1.Haller H, et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med.2011;364:907-917.

  2. ROADMAP trial: Occurrence of microalbuminuria during the 48-month follow-up period in the two study groups 1.Haller H, et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med.2011;364:907-917.

  3. ROADMAP trial: olmesartan delays onset of albuminuria, while increasing mortality 1.Haller H, et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med.2011;364:907-917.

  4. Randomized Olmesartan And Diabetes MicroAlbuminuriA Prevention (ROADMAP) trial Conclusion • Olmesartanwas associated with a delayed onset of microalbuminuria. • The higher rate of fatal cardiovascular events with olmesartan among patients with pre-existing coronary heart disease is of concern. 1.Haller H, et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med.2011;364:907-917.

More Related